Full-Time

Senior Manager

Analytical Development and Quality Control

Posted on 11/27/2024

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Biotechnology
Healthcare

Compensation Overview

$160k - $170kAnnually

Senior

San Bruno, CA, USA

Hybrid position requiring 3 days/week at Pliant in South San Francisco.

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • B.S. in Chemistry or relevant technical field, advanced degree preferred.
  • A minimum of 8 years’ experience in analytical development of new chemical entities in the pharmaceutical industry including managing methods development, validation, and testing at contract testing laboratories.
  • Must have hands-on experience with analytical development techniques used in pharmaceutical industry including LC, LC-MS, GC, and Dissolution.
  • Comprehensive working knowledge of GLPs and GMPs as they relate to drug development and analytical testing.
  • Excellent written and verbal communication skills and organizational skills as well as ability to prioritize and manage multiple tasks under tight timelines.
  • Ability to engage collaboratively with CMC functions, with other functions within Pliant, and with external testing laboratories.
Responsibilities
  • Manage the development, qualification/validation, and transfer of analytical methods at contract laboratories. Review analytical data from contract partners, provide feedback and facilitate resolution of technical or quality issues.
  • Manage CMOs/CROs testing labs for all analytical development and quality control activities
  • Assist in selection and management of contract laboratories.
  • Collaborate with other members of CMC team to ensure timely release of clinical products and resolution of product investigations.
  • Author and review technical reports, deviations, and change control documents.
  • Summarize experimental findings, review, and interpret development and stability study results, and assemble analytical data packages to support regulatory submissions.
  • Manage sample inventory and support miscellaneous activities, such as shipping etc.

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, proteins that help cells stick together and communicate. This focus allows Pliant to create specific and effective therapies for various fibrotic conditions. Unlike many competitors, Pliant emphasizes a deep understanding of fibrosis and integrin biology, which informs their drug development process. The company's goal is to stop the progression of fibrotic diseases and restore normal organ function, ultimately improving the lives of patients affected by these conditions.

Company Stage

IPO

Total Funding

$201.4M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

6%

1 year growth

12%

2 year growth

49%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.

Help us improve and share your feedback! Did you find this helpful?